Board of Directors

Director since November 2018

Age 66

Mr. Aguirre is the former Chairman, President and Chief Executive Officer of Chiquita Brands International, Inc. (“Chiquita”), a global distributor of consumer products, having served as Chiquita’s President and Chief Executive Officer from January 2004 to October 2012 and its Chairman from May 2004 to October 2012. Prior to joining Chiquita, Mr. Aguirre worked for more than 23 years in brand management, general management and turnarounds at The Procter & Gamble Company (“P&G”), a manufacturer and distributor of consumer products. Mr. Aguirre began his P&G career in 1980, serving in various capacities including President and General Manager of P&G Brazil, President of P&G Mexico, Vice President of P&G’s global snacks and U.S. food products, and President of global feminine care. Mr. Aguirre was a member of the board of directors of Aetna from 2011 until the closing of the Aetna merger transaction in November 2018, when he became a director of CVS Health. Mr. Aguirre also serves as a director of Barry Callebaut AG, a manufacturer of high-quality chocolate and cocoa products, and Synchrony Financial, a consumer financial services company.

Mr. Aguirre brings to the Board extensive consumer products, global business and executive leadership experience. As a former Chairman and CEO of a large public company that produces and distributes consumer products worldwide, he has significant brand management and international experience that is valuable to the Board’s strategic and operational understanding of global markets. Mr. Aguirre’s experience and service on other large public company boards, where he has chaired various committees, positions him well as the Chair of our Audit Committee and a member of our Management Planning and Development Committee.

Director since September 2022

Age 62

Dr. Balser has served as the chief executive of Vanderbilt University Medical Center (“VUMC”) since 2009, and has been President and Chief Executive Officer of VUMC since 2016, when it became an independent health care company. He has also served as Dean of the Vanderbilt University School of Medicine since 2008. Dr. Balser is a member of the National Academy of Medicine and serves on its governing council. He previously served on the board of Varian Medical Systems, Inc. (NYSE: VAR; “Varian”), an oncology treatment device and software maker, from October 2018 until Varian was acquired by Siemens Healthineers AG in April 2021.

Dr. Balser’s business experience includes large regional quaternary health delivery system leadership, human capital management, senior business management experience including a number of community hospital and medical practice acquisitions, overall risk management expertise through oversight of VUMC’s quality, compliance and corporate integrity activities, and financial expertise through management of its P&L and balance sheet and its separation from Vanderbilt University. His experience as a physician scientist includes leading NIH-funded research in various areas of pharmacogenomics and spearheading growth in personalized medicine at VUMC from research concepts to bedside care, integrating advances in informatics, discovery science, and precision genomics. He received a B.S. degree in Biomedical Engineering from Tulane University and an M.D. and Ph.D. in Pharmacology from Vanderbilt. Dr. Balser’s extensive experience in a wide range of roles across health care organizations is a tremendous asset for the Board and its Health Services and Technology Committee. The Board believes that Dr. Balser’s deep clinical experience adds knowledge and leadership depth and that he brings great value to the Board and its committees.

Director since March 2007

Age 72

Mr. Brown has been a partner of Nelson Mullins Riley & Scarborough LLP ("Nelson Mullins"), a national law firm, since the August 2018 merger of Nelson Mullins and the Florida law firm of Broad and Cassel, of which he served as Chairman from March 2000 through the time of the merger. He was also a member of the executive committee of Nelson Mullins until he rotated off of the committee in December 2021. Mr. Brown served as a lead director of Rayoner Advanced Materials, Inc., a specialty cellulose production company until his retirement from the board in May 2020. Mr. Brown previously served on the Board of Caremark Rx, Inc. from March 2001 until March 2007 closing of the merger transaction involving Caremark and CVS Health, when he became a director of CVS Health.

Mr. Brown’s legal and health care expertise and experience are highly valued by the Board, as is his ability to analyze and interpret complex issues and facilitate Board engagement. Mr. Brown has significant health care experience, including through his oversight of UF Health while serving as Chairman of the Board of Trustees for the University of Florida and as a member of the Board of Directors and Executive Committee of Orlando Health, a not-for-profit health care network. The Board believes that Mr. Brown’s experience adds knowledge and leadership depth to the Board.

Director since March 2015

Age 69
Ms. DeCoudreaux is the President Emerita of the former Mills College, a liberal arts college for women with graduate programs for women and men, which is now known as Mills College at Northeastern University, having served a five-year term in that position from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company (“Eli Lilly”), a global pharmaceutical manufacturer, including as vice president and deputy general counsel, specialty legal team, from 2010-2011, vice president and general counsel, Lilly USA, from 2005-2009, and secretary and deputy general counsel of Eli Lilly from 1999-2005. During her 30-year career with Eli Lilly Ms. DeCoudreaux also previously served as an executive director of Lilly Research Laboratories, director of federal government relations, director of state government relations and director of community relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational and for profit and non-profit boards of trustees, including as both a trustee and board chair at Wellesley College. She currently serves as lead independent trustee and Chair of the board of the Parnassus Funds Trust, Parnassus Income Funds Trust, a family of investment funds that integrates environmental, social and governance (ESG) factors and fundamental investment principals.

Ms. DeCoudreaux has more than 30 years of experience in the pharmaceutical industry, and her experience as an attorney in that field and in the area of corporate governance makes her a great asset to our Board.

Director since September 2013

Age 67

Ms. DeParle is a Managing Partner of Consonance Capital Partners, LLC, a private equity firm focused on investing in small and mid-size health care companies since March 2020, and was a Partner from August 2013 until March 2020. She is also a Co-Founder of the firm. From March 2009 to January 2013, Ms. DeParle served in the White House, first as Counselor to the President and Director of the White House Office of Health Reform, and later as Assistant to the President and Deputy Chief of Staff for Policy. In addition, from 1993 to 2000, Ms. DeParle served as the Associate Director for Health and Personnel for the White House Office of Management and Budget, and later as the Administrator of the Centers for Medicare and Medicaid Services (then known as the Health Care Financing Administration). From 2001 to March 2009, Ms. DeParle served as a Senior Advisor with JPMorgan Partners and as a Managing Director of its successor entity, CCMP Capital, L.L.C., focusing on private equity investments in health care companies. Ms. DeParle is also a director of HCA Holdings, Inc., a health care services company that owns, manages or operates hospitals and various other health care facilities.

Ms. DeParle has more than 25 years of experience in the health care arena, and is widely considered to be one of the nation’s leading experts in health care policy, management and financing, which makes her an excellent fit for our Board. Her background in public policy and government affairs, legal and regulatory compliance, and corporate governance and sustainability make her an excellent Chair of our Nominating and Corporate Governance Committee.

Director since November 2018

Age 71

Mr. Farah has been the Chair of the Board of CVS Health Corporation since May 2022. He is the former Chairman of the Board and a director of Tiffany & Co., a retailer of jewelry and specialty products. He served as Executive Director of Tory Burch LLC, a retailer of lifestyle products, from March 2017 to September 2017, having previously served as Co-Chief Executive Officer and director from September 2014 to February 2017. He is former Executive Vice Chairman of Ralph Lauren Corporation, a retailer of lifestyle products, having served in that position from November 2013 to May 2014, and previously served as President and Chief Operating Officer (“COO”) from April 2000 to October 2013, and Director from April 2000 to August 2014. During his 40-plus year career in retailing, Mr. Farah also held director and/or executive positions with Venator Group, Inc. (now Foot Locker, Inc.), R.H. Macy & Co., Inc., Federated Merchandising Services, the central buying and product development arm of Federated Department Stores, Inc., Rich’s/Goldsmith’s Department Stores, and Saks Fifth Avenue, Inc. Mr. Farah was a member of the board of directors of Aetna from 2007 until the closing of the Aetna Transaction, when he became a director of CVS Health. He was a director of Metro Bank PLC, a financial services company, until his retirement from that board in March 2020, and a director of Tiffany until its sale to LVMH in January 2021. He currently serves as a director of The Progressive Corporation, an auto insurance company.

Mr. Farah brings extensive business and leadership experience to our Board. He has strong marketing, brand management and consumer insights developed in his over 40 years of experience in the retail industry. His former positions as Executive Vice Chairman, President and COO of Ralph Lauren and Executive Director and Co-CEO of Tory Burch give Mr. Farah important perspectives on the complex financial and operational issues facing the Company. His experience as a board chair and executive leading consumer-facing companies makes him very well suited to serve as the Executive Chair of our Board.

Director since January 2011

Age 71

Ms. Finucane has been a Senior Advisor of the TPG Rise Climate Fund (“TPG”), an investment fund focused on various climate sub-sectors, since September 2022 and the Chair of Rubicon Carbon, a carbon credit firm and a TPG portfolio company, since November 2022. Previously Ms. Finucane served as Chairman of the Board of Bank of America Europe DAC from July 2018 through December 2022. She also served as a Vice Chairman of Bank of America Corporation (“Bank of America”), an international financial services company, from July 2015 until her retirement in December 2021. From 2006 through July 2015, Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. As a member of the executive management team, Ms. Finucane was responsible for the strategic positioning of Bank of America and led the company’s environmental, social and governance, sustainable finance, capital deployment and public policy efforts. She established and co-chaired the company’s Sustainable Finance Committee, which included a $1 trillion environmental business initiative, deploying capital to help accelerate the transition to a lower carbon, sustainable economy, and was chair of the company’s ESG Committee. She currently also serves as a director of Williams Sonoma, Inc., a retailer of kitchen and home products.

Ms. Finucane’s experience in the financial services industry, consumer policy, strategy, marketing, corporate social responsibility, and government affairs provides the Board with valuable insight in those key areas. Her distinguished career in banking also makes her a valued member of our Audit Committee and our Management Planning and Development Committee.

Member since October 2024

Age 60

David Joyner is President and Chief Executive Officer of CVS Health, leading more than 300,000 colleagues who are passionate about building a world of health around every consumer. The Company touches the lives of more than 100 million people through its health care benefits and pharmacy benefits management businesses and presence in over 9,000 community health destinations across the United States.

David brings more than 37 years of health care and pharmacy benefit management experience to the company. He was formerly Executive Vice President and President of Pharmacy Services for the Company from January 2023 until October 2024. David formerly served on the boards of several private equity-backed health care companies. He also served as an advisor to the founder and chief executive officer of gWell, a precision health and medicine company focused on providing value-based condition management to payors and employers. David began his career at Aetna as an employee benefit representative before joining Caremark Prescription Services as a regional sales manager. He then served as executive vice president of sales and account services at CVS Caremark and executive vice president of sales and marketing at CVS Health.

David holds a bachelor’s degree in finance from The Rawls College of Business at Texas Tech University, where he currently sits on the advisory council.

Director since October 2023

Age 56

Mr. Kirby has been the Chief Executive Officer and a member of the Board of Directors of United Airlines Holdings, Inc. (“United Airlines”; NYSE: UAL), an international air carrier, since May 2020. Mr. Kirby serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 until May 2020, Mr. Kirby was President of United Airlines and was responsible for its operations, marketing, sales, alliances, network planning and revenue management. Mr. Kirby is a well-known airline industry veteran, with a broad and accomplished three-decade-long career in significant leadership roles. Prior to joining United Airlines Mr. Kirby was President of American Airlines from December 2013 until August 2016, and he was President of US Airways from September 2006 until December 2013, when US Airways merged with American Airlines. He started his career at the Pentagon and in the technology sector. Mr. Kirby is a member of the Board of Directors of SONIFI Solutions, a privately held manufacturer of integrated technology and service platforms. He also currently serves as the Chairman of the Star Alliance Chief Executive Board, a global alliance consisting of 26 member airlines. and is a member of the Board of Governors of the International Air Transport Association, a trade association comprised of 240 of the world’s airlines. He is also a member of the Board of Directors of the U.S. Air Force Academy Foundation.

Mr. Kirby is a well-known airline industry veteran, with a broad and accomplished three-decade-long career in significant leadership roles. Mr. Kirby brings valuable expertise to the Board from his experience with marketing, sales, alliances and network planning at United Airlines, as well as his education and background in technology. As CEO of a large public company who is responsible for its business and ongoing operations, he has experience and understanding of how to implement strategic priorities. These skills make him well qualified to serve as a member of our Health Services and Technology Committee.

Director since November 2023

Age 59

Mr. Mahoney has been the President of Boston Scientific Corporation (“Boston Scientific”), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson’s DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. From October 2015 until September 2023 Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc., a multinational health care company.

Mr. Mahoney has extensive experience leading global, medical products companies, including most recently as Chairman, President and Chief Executive Officer of Boston Scientific Corporation. His management experience includes leading complex organizations in medical device and other healthcare-related businesses, expertise in building strong leadership teams, developing international markets, and a proven ability to execute successful business strategies and drive operational excellence. Mr. Mahoney also has significant knowledge of the global medical products business and extensive experience leading and operating within global, multi-faceted medical products companies as a result of his roles at Boston Scientific and Johnson & Johnson.

Director since March 2007

Age 73

Mr. Millon is the retired former President and Chief Executive Officer of PCS Health Systems, Inc., (“PCS”), a pharmacy benefit management company. Mr. Millon joined PCS in 1995, where he served as President and Chief Executive Officer from June 1996 until his retirement in September 2000. Prior to that, Mr. Millon served as an executive and held several global leadership positions with Eli Lilly and Company. Mr. Millon previously served on the board of Caremark from March 2004, upon Caremark’s acquisition of AdvancePCS, and as a director of AdvancePCS (which resulted from the merger of PCS and Advance Paradigm, Inc.) beginning in October 2000. He became a director of CVS Health upon the closing of the merger transaction involving CVS Health and Caremark. Mr. Millon has over 10 years of financial management experience and fifteen years of general functional management experience, including strategic planning experience specific to pharmacy benefit management companies as the former head of PCS. He also has extensive venture capital and public and private company board experience.

Mr. Millon’s extensive background and experience in the pharmacy benefit management, pharmaceutical and life sciences businesses, combined with his financial expertise, provide the Board with additional perspective across the enterprise and make him well qualified to serve as Chair of our Health Services and Technology Committee.

Director since November 2024

Age 58

Ms. Norwalk has served as Strategic Counsel to health care companies at Epstein, Becker & Green, P.C., a national law firm, since 2007. She also advises companies through EBG Advisors, a national strategy and management consultancy, and National Health Advisors, an advocacy firm. She serves as an advisor to private equity investors, including three private equity firms, particularly on health care matters. Ms. Norwalk currently sits on the boards of directors of Arvinas, ModivCare, Neurocrine Biosciences, Globus, and several privately held health care corporations. She is also a member of APCO Worldwide’s International Advisory Council. Ms. Norwalk formerly sat on the boards of NuVasive, Magellan Health, Centene and Endologix, and is the former Acting Administrator for CMS under the George W. Bush administration.

Ms. Norwalk has deep knowledge of, and experience with, the health care industry and government regulations, as well as corporate governance, health care compliance and risk management. These qualities make her a valued member of our Board and its Health Services and Technology Committee.

Director since November 2024

Age 55

Mr. Robbins is the Founder, Portfolio Manager and Chief Executive Officer of Glenview Capital Management. Prior to founding Glenview in 2000, Mr. Robbins spent six years as an analyst and partner at Omega Advisors on their U.S. equity long/short team. He joined Omega after three years at Gleacher & Company, a merger and acquisition advisory boutique in New York. For 30 years, Mr. Robbins has been a portfolio manager analyzing and advising leading publicly traded companies on financial reporting and controls, capital allocation and capital markets strategy and a broad range of governance, operational, communication and strategic issues. Mr. Robbins has been lead independent director and a member of the board of directors of Butterfly Network, Inc., a medical digital imaging company, since 2021.  He is also an active supporter of education reform and serves as chairman of the board for Together Education, and he is a board member for the Relay Graduate School of Education, Robin Hood Foundation and Zearn. 

Mr. Robbins is recognized as a seasoned investor with deep health care investing expertise. His leadership experience and success in advising companies throughout the health care sector are welcomed by the Board.

Director since November 2024

Age 60

Mr. Sansone has served as the Co-Founder, Chairman and Chief Executive Officer of H2 Health, a leading regional provider of physical rehabilitation services and clinician staffing solutions, since February 2020. Prior to that, he served as Managing Director at Alvarez & Marsal in New York, a financial advisory and consulting firm notable for its work in turnaround management and performance improvement of a number of large, high- profile businesses across the globe, where he served as Chairman of the firm’s Healthcare Industry Group, which he founded in 2004. Mr. Sansone is a member of the board of directors of several publicly traded and privately held health care companies, including Pediatrix Medical Group (formerly Mednax), Longevity Health Plans, Carisk Partners, Ovation Healthcare and ChenMed, and formerly served on the board of directors of Magellan Healthcare and Brookdale Senior Living.

Over the past 20 years, Mr. Sansone has invested in and consulted as an executive to numerous companies, particularly in health care, focusing on developing and evaluating strategic and operating alternatives designed to enhance value. His experience and expertise in the health care industry and in finance make him an excellent addition to our Board and its Audit Committee.

Director since May 2017

Age 68

Since October 2018, Ms. Schapiro has been Vice Chair for Public Policy and Special Advisor to the Chairman and Founder of Bloomberg, L.P. She was Vice Chair of the Board of the Value Reporting Foundation, formerly the Sustainability Accounting Standards Board, until the Value Reporting Foundation was absorbed into the International Financial Reporting Standards Foundation in 2022. From January 2014 until December 2018 , Ms. Schapiro served as the vice chair of Promontory Advisory Board, part of Promontory Financial Group, a leading strategy, risk management and regulatory compliance firm. From January 2009 through December 2012, Ms. Schapiro was Chairman of the U.S. Securities and Exchange Commission (SEC), becoming the first woman to serve as that agency’s Chairman. Prior to becoming SEC Chairman, Ms. Schapiro was Chairman and CEO of the Financial Industry Regulatory Authority (FINRA) from 2006 through 2008, and prior to that held a number of key executive positions at FINRA and its predecessor from 1996 through 2006. She also served as Chairman of the Commodity Futures Trading Commission (CFTC) from 1994 to 1996, and was the first person to serve as Chairman of both the CFTC and the SEC. Ms. Schapiro is also currently a director of Morgan Stanley, a financial services company.

Ms. Schapiro’s experience in leading the SEC, FINRA and the CFTC makes her extremely well qualified to serve on our Board. Ms. Schapiro’s leadership of the SEC during the turbulent period that followed the 2008 financial crisis, one of the busiest rulemaking periods in the agency’s history, demonstrates her ability to navigate through a difficult and complex regulatory and political environment. The Board believes that her skills fill important needs in the areas of legal and regulatory compliance, finance, risk management, and public policy and government affairs.

Director since November 2024

Age 57

Mr. Shulman has served as Chief Executive Officer of OneMain Financial, a financial services company that is a leader in offering nonprime customers responsible access to credit, since 2018, and has been Chairman of the Board of OneMain since 2021. Prior to joining OneMain, Mr. Shulman was Senior Executive Vice President, Global Head of Client Service Delivery and was a member of the Executive Committee at BNY Mellon, a global financial services firm. Prior to BNY Mellon, he was a Senior Advisor at McKinsey & Company, and from 2008 to 2012, he served as the Commissioner of the Internal Revenue Service (IRS), where he directed a transformation of the agency’s technology, drove customer service metrics to historic levels and led important breakthroughs in addressing international tax evasion.

Mr. Shulman has significant experience managing large, complex organizations at the intersection of financial services, data and technology. His background in technology and operations, his financial and risk management expertise, and his regulatory and human capital management experience are highly valued by the Board.